DBV Technologies S.A. (DBVT)
Healthcare
- Fundamental
- 2
- Sentiment
- 3
- Technical
- 2
Do Nothing: fundamentalScore is 2 (below required floor of 3); avgDollarVolume20 is only $4.46M, also below the $5M liquidity floor.
Company overview
DBV Technologies S.A. is a clinical-stage biopharmaceutical company based in Montrouge, France, specializing in epicutaneous immunotherapy solutions. Its main product, Viaskin Peanut, targets peanut allergies and has completed Phase III trials. The company is also developing treatments for milk and egg allergies and a booster vaccine for Bordetella pertussis.
Fundamental
weakDBVT's fundamentals are weak, with heavy cash burn and reliance on regulatory milestones and external financing.
FundamentalScore 2/5: DBVT has meaningful cash on hand and management guides to runway into Q3 2027, but it is still pre-commercial with heavy losses and cash burn; the investment case hinges on the planned Viaskin Peanut BLA (Q3 2026) and future financing/dilution risk.
Sentiment
fairSentiment is mixed, with potential catalysts but overshadowed by dilution risks.
Near-term newsflow is anchored by the July 16 financial results/business update (supported by an 8-K per upstream log) and the July 17 $150M ATM prospectus filing; media tone over the last ~14d is neutral and cooler than the prior 30–90d baseline. Red-Flag Screen: **moderate cap (≤3)** due to dilution/supply overhang risk from the ATM program; no regulator-confirmed investigations detected (court-record scan was access-blocked by CAPTCHA).
Technical
weakDBVT is in a bearish trend, with price below major averages and low momentum.
Score 2/5: oversold conditions can fuel a reflex bounce, but DBVT remains below SMA20/50/200 and EMA9/21, MACD is below both signal and zero, ADX is elevated in a bearish trend, and the green day came on lighter volume than the recent selloff.
You’re looking at 2026-07-23 — about 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.